Search Medical Condition
Please enter condition
Please choose location from dropdown

Granollers, Spain Clinical Trials

A listing of Granollers, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (192) clinical trials

Enteral Nutrition and Vasoactive Drugs

Nutrition support in critically ill patients undergoing vasoactive support due to hemodynamic instability is controversial and challenging. However, if it is delivered according to an enteral nutrition protocol and under proper medical supervision, it can be feasible and safe. The present multicenter prospective study was designed to examine the feasibility ...

Phase N/A

9.57 miles

Learn More »

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

COMBAT-MI is an investigator-driven, randomized, double-blind and placebo-controlled clinical trial aimed at evaluating the effect of Remote Ischemic Conditioning and exenatide, alone and in combination, on Myocardial Infarct size in 400 STEMI patients (ST segment elevation myocardial infarction). Patients with TIMI (Thrombolysis in Myocardial Infarction) flow grade > 1 will ...

Phase

9.57 miles

Learn More »

Isolation of Pulmonary Veins With the Aid of Magnetic Resonance Imaging

Atrial fibrosis is a hallmark of the AF substrate. An accurate identification and localization of myocardial fibrosis areas prior to an ablation procedure by means of LGE-MRI might help to target atrial areas harboring AF, thereby improving ablation outcomes and reducing AF recurrences. In order to test this hypothesis, we ...

Phase

9.57 miles

Learn More »

Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event

The purpose of this study is to assess the efficacy and safety of S 44819 in enhancing functional recovery after an ischemic stroke.

Phase

9.57 miles

Learn More »

Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)

Phase I dose ascending ("best of five") clinical trial. First group will start by intranodal injection in cervical lymph nodes of 5*10^6 tolDC-VitD3. Up titration depending on security outcomes to 1010^6 tolDC-VitD3, same route in second cohort dose and next uptitration to 1510^6 tolDC-VitD3. Six cycles per patient with the ...

Phase

9.57 miles

Learn More »

Safety and Immunogenicity Study of DNA.HTI and MVA.HTI in HIV-1-positive Patients(AELIX-002)

AELIX Therapeutics in collaboration with IrsiCaixa has developed a novel immunogen, termed HTI which was designed as an immunogen for T cells to be used as a a therapeutic HIV vaccine that could help HIV infected individuals to control viral replication in the absence of antiretroviral treatment. HTI is a ...

Phase

9.57 miles

Learn More »

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

The purpose of this study is to demonstrate the impact of secukinumab on progression of structural damage in the spine, as measured by the mSASSS in patients with AS.

Phase

9.57 miles

Learn More »

Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic

It's been demonstrated that the HIV-1 virus is associated to the reduction of the microbiota. Some studies suggest that because of this bacterial reduction, the premature aging appears. So this study aims to demonstrate that our probiotic can balance the microbiota as a preventive solution for the inflammaging.

Phase N/A

9.57 miles

Learn More »

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

Study AG348-C-007 is a multicenter study designed to evaluate the efficacy and safety of treatment with AG-348 in approximately 15-20 adult participants with pyruvate kinase deficiency (PKD), who are regularly receiving blood transfusions. The study is comprised of two parts. During the Part 1 Dose Optimization Period of the study, ...

Phase

9.57 miles

Learn More »

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage of all cancers and for 10% of all hematologic malignancies. Subjects with relapsed/refractory multiple myeloma (RRMM) will be included in this study, to evaluate the efficacy and safety of GSK2857916 monotherapy. Subjects will be treated with GSK2857916 monotherapy ...

Phase

9.57 miles

Learn More »